Case Background:
This is a federal securities fraud class action lawsuit on behalf of those who purchased or otherwise acquired Acelyrin, Inc. (“Acelyrin”) (NASDAQ: SLRN) securities (1) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Offering Documents”) issued in connection with the initial public offering (“IPO”) on or around May 4, 2023, inclusive (the “Class Period”)
The complaint alleges that, in the Offering Documents and throughout the Class Period, Defendants made materially false and misleading statements regarding the company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the Part A efficacy results for izokibep, Acelyrin’s lead product candidate to treat hidradenitis suppurativa, would not be indicative of future success and omitted a nearly 30% dropout rate; (2) accordingly, Acelyrin overstated izokibep's clinical and/or commercial prospects; (3) as a result, Acelyrin also overstated the company's business prospects post-IPO; and (4) as a result of the foregoing, Defendants’ statements about the company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times.
Current Status of Case:
On February 19, 2026, Defendants filed a Motion to Dismiss the Second Amended Complaint. This action is ongoing.
If you wish to discuss this action or have any questions, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453; toll-free at (844) 887-9500; or via e-mail at info@ktmc.com.
If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.